Neuronetics Announces Aetna Policy Update Expands TMS Availability For Adolescents With Depression
Portfolio Pulse from Benzinga Newsdesk
Neuronetics, Inc. (NASDAQ:STIM) announced that Aetna has updated its TMS coverage to include adolescents aged 15 and older with major depressive disorder. This follows FDA clearance for NeuroStar TMS as a first-line add-on treatment for adolescents aged 15-21. The policy update is effective immediately.
July 22, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neuronetics, Inc. (NASDAQ:STIM) announced that Aetna has updated its TMS coverage to include adolescents aged 15 and older with major depressive disorder. This follows FDA clearance for NeuroStar TMS as a first-line add-on treatment for adolescents aged 15-21. The policy update is effective immediately.
The expansion of Aetna's TMS coverage to include adolescents is a significant development for Neuronetics. This policy update, combined with recent FDA clearance, is likely to increase the adoption of NeuroStar TMS, potentially boosting Neuronetics' revenues and market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100